WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
1. (WO2012106302) COMBINATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/106302    International Application No.:    PCT/US2012/023261
Publication Date: 09.08.2012 International Filing Date: 31.01.2012
A61K 31/416 (2006.01), A61K 31/47 (2006.01), C07D 231/56 (2006.01)
Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED [GB/GB]; 980 Great West Road Brentford, Middlesex TW8 9GS (GB) (For All Designated States Except US).
SUNNYBROOK RESEARCH INSTITUTE [CA/CA]; A3 33, 2075 Bayview Avenue Toronto, Ontario M4N 3M5 (CA) (For All Designated States Except US).
KUMAR, Rakesh [US/US]; (US) (For US Only).
KERBEL, Robert S. [CA/CA]; (CA) (For US Only)
Inventors: KUMAR, Rakesh; (US).
KERBEL, Robert S.; (CA)
Agent: YOUNG, J. Scott; c/o GlaxoSmithKline Global Patents Department Five Moore Drive P. O. Box 13398 Research Triangle Park, NC 27709 (US)
Priority Data:
61/438,426 01.02.2011 US
Abstract: front page image
(EN)The present invention relates to a method of treating breast cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a breast cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7] indolizino [1,2-b]quinoline-3,14-(4H,12H)-dione, or a pharmaceutically acceptable salt thereof, to a human in need thereof.
(FR)La présente invention porte sur un procédé de traitement du cancer du sein chez l'homme et sur des associations pharmaceutiques utiles dans un tel traitement. En particulier, le procédé de traitement du cancer du sein comprend l'administration de 5-[[4-[(2,3-diméthyl-2H-indazol-6-yl)méthylamino]-2-pyrimidinyl]amino]-2-méthylbenzènesulfonamide, ou d'un sel pharmaceutiquement acceptable de celui-ci, et de (S)-10-[(diméthylamino)méthyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoléine-3,14-(4H,12H)-dione, ou d'un sel pharmaceutiquement acceptable de celle-ci, à un être humain qui en a besoin.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)